Product rebranding as TutiviaT

RNS Number : 4499B

Verici Dx PLC

03 October 2022

 

RNS REACH

Verici Dx plc

("Verici Dx" or the "Company") 

Product rebranding as Tutivia™

Verici Dx's post-transplant test, Tuteva, to be rebranded as Tutivia ™

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that itspost-transplant blood test focused on acute rejection, has been rebranded as Tutivia™.

Tutivia™ (formerly known as Tuteva), is a blood-based RNA signature for a risk score for acute rejection, and will be the first test commercialised on the Verici transplant biomarker platform , with a soft commercial launch in the United States expected later in 2022.

The first three products on the platform are:

· Clarava™ , a pre-transplant prognosis test for the risk of early acute rejection;

· Tutivia™, a post-transplant test focused upon acute rejection, including sub-clinical rejection; and

· Protega™ , a post-transplant test that aims to predict the risk of fibrosis and long-term graft failure

Enquiries:

Verici Dx	www.v ericidx .com
Sara Barrington, CEO	Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: [phone]
Aubrey Powell / Kailey Aliyar / Sam Butcher
Walbrook PR Limited	Tel: [phone] or  [e-mail]
Paul McManus / Sam Allen	Mob: [phone]

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.  The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

 

END

 

 

NRAFSIFFEEESELS